Perspectives on Cancer Drug Development Costs in JAMA

By James Love Vinay Prasad and Sham Mailankody’s JAMA Internal Medicine study on the costs of research and development (R&D) when bringing a single cancer drug to market has sparked renewed discussion about how to measure R&D costs as well … Continue reading →